Blood Tests for Measuring LDL B (Small, Dense LDL Particles)
Direct Answer
There is no single standardized blood test specifically labeled "LDL B" in routine clinical practice; however, small, dense LDL particles are best quantified by measuring apolipoprotein B (apo B), which provides a direct count of all atherogenic particles including small, dense LDL. 1, 2
Understanding the Relationship Between Apo B and Small, Dense LDL
Apo B measurement captures the total number of atherogenic particles, including small, dense LDL (LDL B), because each LDL particle—regardless of size or density—contains exactly one apo B molecule. 1, 3
Small, dense LDL particles are particularly atherogenic and are commonly elevated in patients with diabetes mellitus, metabolic syndrome, hypertriglyceridemia, and insulin resistance—conditions where LDL cholesterol may appear normal but particle number (apo B) is elevated. 2, 4
The pattern of elevated triglycerides, low HDL cholesterol, and increased small, dense LDL particles is captured more accurately by apo B than by LDL cholesterol measurement alone. 5
Available Testing Methods
Apolipoprotein B Testing (Preferred Method)
Apo B is measured by fully automated turbidimetric immunoassay and provides a direct particle count of all atherogenic lipoproteins (VLDL, IDL, and LDL). 4
Apo B does not require fasting and remains accurate even with moderately elevated triglycerides, unlike calculated LDL cholesterol which becomes unreliable when triglycerides exceed 200-400 mg/dL. 1, 6
Apo B measurement has less laboratory error than LDL cholesterol determination, particularly in patients with hypertriglyceridemia. 5
Small, Dense LDL-C Direct Measurement
Small, dense LDL cholesterol (sdLDL-C) can be measured directly using an enzymatic homogeneous assay with automated analyzers, though this is less widely available than apo B testing. 4
Measuring both apo B and sdLDL-C together may provide additional clinical information: patients with familial hypercholesterolemia show higher apo B relative to sdLDL-C, while those with diabetes or metabolic syndrome show higher sdLDL-C relative to apo B. 4
NMR Spectroscopy (Not Recommended for Routine Use)
Nuclear magnetic resonance (NMR) spectroscopy can determine LDL particle number (LDL-P) and particle size, but the American College of Cardiology/American Heart Association explicitly recommends against measuring advanced lipid parameters including NMR-derived particle size and density beyond a standard fasting lipid profile, as they provide no demonstrated benefit. 7
While NMR-derived LDL-P correlates with apo B in most studies, apo B is preferable due to its availability, standardization, scalability, and lower cost. 8
Clinical Indications for Apo B Testing
Measure apo B when triglycerides are ≥200 mg/dL, as this is when LDL cholesterol calculations become unreliable and small, dense LDL particles are likely elevated. 6
Consider apo B measurement in patients with diabetes mellitus, metabolic syndrome, obesity, or insulin resistance—populations where small, dense LDL predominates despite normal LDL cholesterol levels. 2, 3
Apo B ≥130 mg/dL constitutes a risk-enhancing factor corresponding to LDL-C ≥160 mg/dL and should favor more aggressive lipid-lowering therapy. 6
Treatment Targets for Apo B
Very high-risk patients: apo B target <80 mg/dL (corresponding to LDL-C <70 mg/dL). 5, 6
High-risk patients: apo B target <100 mg/dL (corresponding to LDL-C <100 mg/dL). 5, 6
Common Pitfalls to Avoid
Do not order NMR spectroscopy or other advanced lipoprotein testing for routine cardiovascular risk assessment, as guidelines explicitly recommend against this practice. 7
Standard LDL cholesterol measurement significantly underestimates cardiovascular risk in patients with high triglycerides and predominant small, dense LDL particles—use apo B in these situations. 2, 3
While sdLDL-C can be measured directly, apo B is more widely available, better standardized, and captures the total atherogenic particle burden more comprehensively. 8, 4